ActRIIB ectodomain variants treating metabolic disorders and fibrosis

ChangeBridge: Patent Apps - Peptides (C07K)

Published April 2nd, 2026

Detected April 2nd, 2026

Summary

USPTO published patent application US20260092096A1 for Activin receptor type IIB (ActRIIB) ectodomain variants fused to Fc domain for treating metabolic disorders, diabetes, obesity, fibrosis, and muscle atrophy. The application (No. 19206991) was filed May 13, 2025, by inventors Maureen D. O'Connor-McCourt et al.

View original document View source feed page

What changed

USPTO published patent application US20260092096A1 disclosing polypeptides comprising ActRIIB ectodomain variants, optionally fused to an Fc domain moiety. The claimed inventions are directed to treating diseases associated with TGFβ superfamily ligand signaling, including metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and anemia. CPC classifications include C07K 14/71 and A61P 3/04.

This patent application publication does not impose compliance obligations on third parties. Pharmaceutical companies, biotechnology firms, and researchers developing ActRIIB-related therapeutics should review the claims to assess potential freedom-to-operate implications or licensing opportunities. No response or action is required from the public.

Source document (simplified)

← USPTO Patent Applications

ACTIVIN RECEPTOR TYPE IIB VARIANTS AND USES THEREOF

Application US20260092096A1 Kind: A1 Apr 02, 2026

Inventors

Maureen D. O'CONNOR-MCCOURT, Vannakambadi K. Ganesh, Gilles Tremblay, Gauthier Schang

Abstract

There are provided polypeptides that include an Activin receptor type IIB (ActRIIB) ectodomain (ECD) variant. In some embodiments, a polypeptide of the disclosure includes an ActRIIB-ECD variant fused to an Fc domain moiety. The disclosure also provides pharmaceutical compositions and methods of using the polypeptides to treat diseases and conditions associated with TGFβ superfamily ligand signaling, such as metabolic disorders, diabetes, obesity, cardiometabolic disease, pulmonary hypertension, fibrosis, muscle weakness and atrophy, bone damage, and/or low red blood cell levels (such as anemia).